menu
The microbiome therapies pipeline features 260 drugs under evaluation across different phases of development
The microbiome therapies pipeline features 260 drugs under evaluation across different phases of development
The microbiome therapies pipeline features 260 drugs under evaluation across different phases of development

The microbiome therapies pipeline features 260 drugs under evaluation across different phases of development

Manufacturing live biotherapeutic products is bothtechnically challenging and financially demanding; as a result, innovator firmsare becoming increasingly reliant on contract service providers to accessspecialized facilities and optimize overall costs.

 

To order this 300+ page report, which features 140+ figuresand 125+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html

 

The USD 300 million (by 2030) financial opportunitywithin the microbiome contract manufacturing market has been analysed acrossthe following segments:

§ Type of ProductManufactured

§ Active PharmaceuticalIngredients (APIs)

§ Finish DrugFormulations (FDFs)

 

§ Type of Type ofFormulation

§ Solid Formulations

§ Oral Liquids

§ Injectables

§ Others

 

§ Scale of Operation

§ Clinical

§ Commercial

 

§ Company Size

§ Small-sized

§ Mid-sized

§ Large

 

§ Key GeographicalRegions

§ North America

§ Europe

§ Asia-Pacific and Restof the World

 

The NextGeneration Immune Checkpoint Inhibitors and StimulatorsMarket, 2020-2030 report features the following companies, which we identified to be keyplayers in this domain:

§  Bristol Myers Squibb

§  GlaxoSmithKline

§  Incyte

§  Novartis

§  Trillium Therapeutics

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

4. Market Landscape

5. Company Profiles

6. Regional Capability Analysis

7. Likely Partner Analysis 

8. Clinical Trial Analysis

9. Capacity Analysis

10. Demand Analysis

11. Make versus Buy Decision Making Framework

12. Microbiome related initiatives of BigPharmaceutical Players

13. Market Forecast

14. Conclusion

 

15. Executive Insights

 

16. Appendix 1: Tabulated Data

 

17. Appendix 2: List of Companies and Organizations

 

18. Appendix 3: List of Probiotic Supplement ContractManufacturers and       

Microbial Contract Service Providers

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com